MedTrace Logo

Effect of Pyridorin in Patients With Diabetic Nephropathy

NCT00320021 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2006-04-27

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the safety, tolerability and efficacy of Pyridorin (pyridoxamine dihydrochloride) up to 250 mg given orally twice daily in patients with diabetic kidney disease.

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

Pyridorin (pyridoxamine dihydrochloride)

Sponsors & Collaborators

  • BioStratum

    lead INDUSTRY

Principal Investigators

  • Thorsten P Degenhardt, Ph.D. · BioStratum, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Completion
2003-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00320021 on ClinicalTrials.gov